Skip to main content

Medical Services

A long-term safety study of extended-release buprenorphine illustrates a safety profile comparable to that of the sublingual version of the drug.
A virtual Rx Drug Abuse & Heroin Summit session addressed the often overlooked topic of community pharmacists' role in facilitating or blocking access to treatment for opioid use disorder.
Both internal and external considerations are moving more local corrections systems toward maintaining evidence-based care for opioid use disorder.
A longer duration of treatment with the injectable formulation of buprenorphine for opioid use disorder was associated with more favorable abstinence outcomes in a newly published study.
Public health risk is forcing addiction treatment programs to rethink their typical approaches to patient drug testing at this time.
Click here and listen to Dr. Patricia Essilfie, a physician at St. John’s Well Child, as she describes how the once limited resources and treatment plans for smokers at St. John’s, were transformed…
Back to Top